SNOT-22 in a control population by Erskine, SE et al.
 
SNOT 22 in a Control Population 
 
 
The CRES Group 
 
Sally Erskine1,*, Carl Philpott1,22,23, Allan Clark, Steve Morris21, Claire Hopkins2, 
Alasdair Robertson4, Shahzada Ahmed6, Naveed Kara12, Sean Carrie11, Vishnu 
Sunkaraneni20, Jaydip Ray17, Shahram Anari7, Paul Jervis10, Jaan Panesaar18, 
Amir Farboud5, Nirmal Kumar3, Russell Cathcart8, Robert Almeyda14, Hisham 
Khalil9, Peter Prinsley13, Nicolas Mansell15, Mahmoud Salam16, Jonathan 
Hobson19, Jane Woods1 andEmma Coombes 
Aim:	
To	assess	SNOT-22	and	its	subscales	in	a	healthy	UK	wide	population	
	
Methodology/Principle	
This	analysis	uses	data	from	the	‘Chronic	Rhinosinusitis	Epidemiology	Study’	(CRES)	
which	recruited	from	30	centres	across	the	UK,	and	the	‘Characterising	the	sinusitis	
population:	The	socioeconomic	impact	of	Chronic	Rhinosinusitis	Study’	(SocCoR).	250	
healthy	volunteers	were	recruited	as	part	of	these	studies.	Study-specific	questionnaires	
including	demographics,	socioeconomic	factors	and	past	medical	history	as	well	as	
SNOT-22	and	SF-36	were	distributed.	The	healthy	population	(controls)	had	no	self-
reported	nasal	problems	in	the	past,	no	chronic	conditions	undergoing	active	treatment	
and	no	hospital	admissions	in	the	preceding	12	months.	
	
Results:		
The	mean	SNOT-22	total	score	overall	was	12.0.	The	mean	was	10.2	for	males	with	a	
median	of	6.5,	and	a	mean	of	13.2	for	females	with	a	median	of	9.		Females	scored	
significantly	more	highly	than	males	on	the	sleep/fatigue	and	facial	domains.	
	
Conclusions	
Differences	in	SNOT-22	scores	were	identified	between	those	with	different	types	of	
CRS	with	those	with	CRSwNPs	/AFRS	having	significantly	higher	scores	in	the	nasal	
domain	compared	to	those	without	polyps.		
	
	
	
	
Introduction	
Chronic	rhinosinusitis	(CRS)	affects	a	significant	proportion	of	the	population;	a	recent	
European	study	found	a	prevalence	of	11%	(Hastan,	Fokkens	et	al.	2011).	Patient	
reported	outcome	measures	(PROMs)	are	a	means	of	collecting	information	on	the	
effectiveness	of	care	delivered	to	patients	as	perceived	by	the	patients	themselves	and	
are	increasingly	important	in	clinical	practice	and	in	research	(Timmins	2008;	HaSCI	
2014)	(Greenhalgh,	Long	et	al.	2005)	on	a	background	of	increasing	costs	of	healthcare	
across	the	world.	The	most	widely	accepted	and	best	validated	patient	self-report	
symptom	evaluation	tool		for	use	in	CRS	is	the	SNOT-22,	whose	22	items	incorporate	
both	nasal	and	non-nasal	symptoms(Hopkins,	Gillett	et	al.	2009).	Within	SNOT-22,	self-
reported	symptom	severity	is	graded	from	0-5,	with	5	being	a	severe	problem.		It	is	a	
modification	of	the	31-question	Rhinosinusitis	Outcome	Measure	(RSOM-31)(Piccirillo,	
Edwards	et	al.	1995).	Factor	analysis	identifies	four	principal	SNOT	domains	–	nasal,	
facial,	sleep	and	mood	(Browne,	Hopkins	et	al.	2007)	(Lange,	Thilsing	et	al.	2011;	Lange,	
Holst	et	al.	2013;	DeConde,	Mace	et	al.	2014).	Factor	analysis	for	SNOT-22	was	validated	
in	a	Danish	population	of	40	patients	(Lange,	Thilsing	et	al.	2011).The	four	subscales	are	
rhinological	symptoms	(questions	1-5,	7and	8),	ear	and	facial	symptoms	(questions	9-
12),	sleep	function	(questions	13-15)	and	psychological	issues	(questions	17-22).	The	
questions	regarding	cough	and	waking	up	tired	were	not	included	in	these	subscales.	
There	are	few	data	for	‘normal’	non-CRS	patients,	particularly	in	the	UK	population.	
		
The	overarching	aim	of	the	Chronic	Rhinosinusitis	Epidemiology	Study	(CRES)	was	to	aid	
better	understanding	of	medical	and	non-medical	factors	contributing	to	development	
or	worsening	of	CRS.	The	aim	of	SocCoR	was	to	identify	the	socio-economic	costs	of	CRS	
to	improve	the	understanding	of	the	impact	of	CRS	disease	to	the	patient	and	the	NHS.	
The	purpose	of	this	analysis	was	to	yield	large	dataset	of	SNOT-22	information	for	a	
control	population	in	the	UK.	
	
	
Materials	and	Methods	
	
CRES	was	conducted	as	a	cross-sectional	cohort	study	and	recruited	from	a	total	of	30	
sites	 from	 around	 the	 UK	 (including	 the	 devolved	 nations	 of	 Wales	 and	 Scotland),	
between	2007	and	2013.	Controls	 included	 family	 and	 friends	of	 those	attending	ENT	
outpatient	 clinics	 and	 hospital	 staff	who	 had	 no	 diagnosis	 of	 persistent	 nose	 or	 sinus	
problems	 and	 had	 not	 been	 admitted	 to	 hospital	 in	 the	 previous	 12	 months.	
Questionnaires	were	returned	by	participants	using	a	Freepost	envelope	and	scanned	to	
a	secure	database	using	Formic.	Two	members	of	the	research	team	checked	the	accuracy	
of	electronic	scanning	of	returned	questionnaires.	SocCoR	recruited	participants	meeting	
the	same	criteria,	but	only	from	one	site.	
	
The	CRES	was	approved	by	the	Oxford	C	Research	Ethics	Committee,	sponsored	by	the	
University	of	East	Anglia	(UEA)	and	funded	by	the	Anthony	Long	and	Bernice	Bibby	Trusts.	
The	study	specific	questionnaire	was	anonymous	and	therefore	no	consent	was	taken	but	
implied	through	participation.	Participant	information	leaflets	were	provided.		
	
	Results		
A	total	of	251	healthy	volunteers	completed	the	SNOT-22	questionnaire.	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
	
Table	1:	SNOT-22	and	its	subscales	
	
	 	 Age	
(range)	
SNOT-22	 Nasal	 Facial	 Sleep	
fatigue	
Emotional	
	 n	 	 mean	(sd)	 Median	
(IQR)	
mean	(sd)	 mean	(sd)	 mean	(sd)	 mean	(sd)	
Total	 251	 47.5		
(19-80)	
12.0	(13.6)	 8	(2-17)	 2.5	(4.0)	 1.1	(2.5)	 2.9	(3.6)	 3.5	(5.3)	
Females	 143	 46.8	
(14.4)	
19-80	
13.2	(15.0)	 9	(2-18)	 2.3	(3.6)	 1.4	(2.9)	 3.4	(3.9)	 3.8	(6.0)	
Males	 96	 48.8	
(15.8)	
22-82	
10.2	(11.1)	 6.5	(2-14.5)	 2.8	(4.4)	 0.7	(1.4)	 2.2	(2.7)	 3.0	(4.1)	
Differences	
(p	values)	
	 	 0.0921	 0.2973	 0.3632	 0.0061	 0.0051	 0.1931	
	
1t-test	(unequal	variances)	;		2	t-test	(equal	variances)	;	3	Mann-Whitney	test	
	
	
Boxplot	to	show	SNOT-22	for	males	and	females
	
	
	
Females                                      Males 
	
	
Females	tended	to	score	more	highly	than	males	overall.	They	also	had	a	wider	range	of	
scores.	Females	scored	more	highly	on	each	of	the	domains;	this	was	statistically	
significant	within	the	sleep	fatigue	and	facial	domains.		
No	association	was	found	between	SNOT-22	score	and	age	(TBC).	
	
Discussion		
Our	data	describe	a	large	population	of	healthy	volunteers	from	across	the	UK.	We	found	
a	mean	SNOT-22	score	of	10.2	for	males	with	a	median	of	6.5,	and	a	mean	of	13.2	for	
females	with	a	median	of	9.	 	The	standard	deviation	was	higher	amongst	females.	Our	
control	results	were	not	normally	distributed;	this	is	to	be	expected	since	there	should	be	
a	 large	 number	 of	 individuals	who	 score	 very	 low	 (floor	 effect).	 Previous	 studies	 of	 a	
healthy	 control	 population	 have	 found	 a	 median	 of	 7-9	 (Gillett,	 Hopkins	 et	 al.	 2009;	
Gregório,	Andrade	et	al.	2015).		The	population	(n=116)	recruited	by	Gillett	et	al	included	
a	higher	proportion	of	males	and	also	those	recruited	through	a	tennis	club	who	may	have	
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been	healthier	than	the	general	population.		A	study	using	a	random	sample	of	the	Danish	
population	(n=271	for	those	without	CRS)	similarly	found	a	median	SNOT-22	value	of	7	
(IQR2-15),	(Lange,	Holst	et	al.	2013;	Lange,	Thilsing	et	al.	2015);	they	do	not	differentiate	
by	gender.	In	a	study	of	539	healthy	volunteers	in	Sao	Paulo,	Gregorio	et	al	also	found	
SNOT-22	scores	were	distributed	significantly	differently	between	men	and	women.	Men	
presented	significantly	lower	normal	values	than	women	(men:	mean	=	8.58	and	median	
=	7	versus	women:	mean	=	10.94	and	median	=	9;p	=	0.005).	A	median	score	of	7-10	for	
males	and	9-13	for	females	therefore	appears	to	be	reproducible	benchmark	for	‘normal’	
SNOT-22.		This	should	not	be	used	as	an	‘absolute’	normal	score	to	assign	care	for	CRS	or	
as	a	diagnostic	threshold,	but	is	a	useful	figure	to	consider	when	assessing	SNOT-22	in	the	
context	of	CRS	in	both	clinic	and	research.	
	
Conclusion	
Our	data	provide	reference	data	for	scores	across	SNOT-22	in	a	healthy	population	across	
a	 wide	 cross	 section	 of	 the	 UK	 population	 and	 they	 demonstrate	 the	 differences	 in	
reporting	in	males	and	females.	These	data	can	be	used	in	future	studies	for	comparison	
with	different	disease	populations	with	rhinosinusitis.	
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